A Study of DBPR112 in Patients With Head and Neck Cancer and EGFR Mutated Lung Cancer

Conditions:   Head and Neck Cancer;   NSCLC
Intervention:   Drug: DBPR112
Sponsor:   National Health Research Institutes, Taiwan
Recruiting - verified May 2017

http://ift.tt/2uvoeKu